X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

FDA And DEA Join Forces To Increase Stimulant Production

Content Team by Content Team
5th August 2023
in News
FDA And DEA Join Forces To Increase Stimulant Production

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The FDA and DEA are urging drug manufacturers to ramp up production of prescription stimulants, such as Adderall, due to the ongoing shortage that has lasted almost a year.

They indicated in a joint letter that they are working with suppliers, manufacturers, and other interested parties to solve the present shortfall and take precautions against future shortages. The letter acknowledged that the FDA and DEA partnership needed help to solve the problem and urged manufacturers to confirm their efforts to boost production to meet the required quota.

One of the main reasons behind the shortage is the DEA’s yearly limit on amphetamine/stimulant production, with Adderall being classified as a Schedule 2 drug due to its potential for abuse. Last year, amphetamine medications were produced 30% below the total quota, resulting in a shortfall of about 1 billion potential doses. This year, a similar trend is being observed.

Manufacturers unwilling to increase production have been asked to relinquish their remaining 2023 quota allotment, allowing the DEA to allocate it to manufacturers that will increase production.

Both agencies have also called on healthcare providers, payers, and physicians to closely monitor stimulant prescriptions due to their widespread misuse and potential for addiction. The use of amphetamine products and other stimulants saw a 45.5% increase in the U.S. from 2012 to 2021, particularly during the COVID-19 pandemic when virtual prescribing became more prevalent.

The letter emphasised the importance of ensuring access to stimulant medications for those who need them while also taking a closer look at responsible and thoughtful prescription practices.

The shortage of Adderall and other stimulants came to light last summer when major producers reported shortages. The manufacturing disruptions were compounded by a surge in Adderall prescriptions in 2022, attributed to increased diagnoses of attention-deficit/hyperactivity disorder and easier availability through online start-ups.

Previous Post

Swift Biomanufacturing: Automated PAT Systems Efficiency

Next Post

New Trends Revolutionizing Pharma Development And Packaging

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Tjoapack invests in automated injectables packaging capabilities

New Trends Revolutionizing Pharma Development And Packaging

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In